These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22009549)

  • 21. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
    Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathogenesis of atypical femoral fracture].
    Iwata K; Mashiba T
    Clin Calcium; 2016 Jan; 26(1):73-9. PubMed ID: 26728533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy.
    Iwata K; Mashiba T; Hitora T; Yamagami Y; Yamamoto T
    Bone; 2014 Jul; 64():183-6. PubMed ID: 24747352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy.
    Porrino JA; Kohl CA; Taljanovic M; Rogers LF
    AJR Am J Roentgenol; 2010 Apr; 194(4):1061-4. PubMed ID: 20308511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical femoral fractures associated with long-term bisphosphonate use.
    Chatterjee S
    CMAJ; 2013 Oct; 185(14):1248. PubMed ID: 23649415
    [No Abstract]   [Full Text] [Related]  

  • 29. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impending Atypical Femoral Fracture in Patients With Medullary Thyroid Cancer With Skeletal Metastasis Treated With Long-term Bisphosphonate and Denosumab.
    Koizumi M; Gokita T; Toda K
    Clin Nucl Med; 2017 Jun; 42(6):463-464. PubMed ID: 28240655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
    Flores IL; dos Santos-Silva AR; Della Coletta R; Vargas PA; Lopes MA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):e264-8. PubMed ID: 24528798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate-associated atypical femur fracture in a 90-year-old Caucasian woman.
    Gopinath KG; Shibu PK
    Hong Kong Med J; 2015 Jun; 21(3):286.e2-3. PubMed ID: 26045077
    [No Abstract]   [Full Text] [Related]  

  • 35. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.
    Ota S; Inoue R; Shiozaki T; Yamamoto Y; Hashimoto N; Takeda O; Yoshikawa K; Ito J; Ishibashi Y
    Breast Cancer; 2017 Jul; 24(4):601-607. PubMed ID: 27943163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid.
    Tantavisut S; Tanavalee A; Thanakit V; Ngarmukos S; Wilairatana V; Wangroongsub Y
    Clin Orthop Surg; 2014 Sep; 6(3):358-60. PubMed ID: 25177464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient].
    Okagawa Y; Sato Y; Onuma H; Osuga T; Hayashi T; Sato T; Miyanishi K; Kobune M; Takimoto R; Kato J
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):867-70. PubMed ID: 26197752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 39. A rare case of a bisphosphonate-related femoral diaphyseal fracture occurring below a previously fixed compression hip screw (CHS) plate.
    Cho HJ; Suh KT
    J Orthop Sci; 2015 May; 20(3):559-62. PubMed ID: 24379016
    [No Abstract]   [Full Text] [Related]  

  • 40. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.